Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.11)
# 1,338
Out of 4,614 analysts
84
Total ratings
28.33%
Success rate
-12.23%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMTX Immatics | Initiates: Overweight | $19 | $10.84 | +75.28% | 1 | Oct 7, 2024 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $12 → $15 | $3.71 | +304.31% | 3 | Sep 23, 2024 | |
| GILD Gilead Sciences | Maintains: Overweight | $95 | $85.26 | +11.42% | 3 | Sep 11, 2024 | |
| AADI Aadi Bioscience | Downgrades: Neutral | $5 → $1.75 | $1.94 | -9.79% | 3 | Aug 27, 2024 | |
| TSBX Turnstone Biologics | Maintains: Overweight | $20 → $3.75 | $0.46 | +713.80% | 2 | Aug 19, 2024 | |
| IBRX ImmunityBio | Maintains: Neutral | $6 → $4.75 | $3.53 | +34.75% | 4 | Aug 19, 2024 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $36 | $24.89 | +44.64% | 2 | Aug 15, 2024 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $19 → $10 | $10.13 | -1.26% | 8 | Jul 29, 2024 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $40 | $13.87 | +188.39% | 5 | Jul 8, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $15 | $9.58 | +56.58% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $10.19 | -1.82% | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $48 → $51 | $54.28 | -6.04% | 7 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $21.71 | +61.22% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2.25 → $3.5 | $1.19 | +195.36% | 3 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.87 | +140.64% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $6.92 | +333.53% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.15 | +534.92% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.00 | +100.00% | 3 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 | $59.52 | +76.43% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $1.47 | +582.59% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $43 | $47.09 | -8.69% | 1 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $7 | $2.75 | +154.55% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $17.14 | +191.72% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.86 | +162.39% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $3.54 | +606.21% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $28 | $26.37 | +6.18% | 1 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $19.79 | +1.09% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $20 | $6.00 | +233.33% | 1 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.27 | +18.11% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $0.51 | +1,872.39% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.71 | +421.61% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $2.76 | +2,073.91% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $7.08 | +154.42% | 3 | Apr 7, 2020 |
Immatics
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $10.84
Upside: +75.28%
Black Diamond Therapeutics
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $3.71
Upside: +304.31%
Gilead Sciences
Sep 11, 2024
Maintains: Overweight
Price Target: $95
Current: $85.26
Upside: +11.42%
Aadi Bioscience
Aug 27, 2024
Downgrades: Neutral
Price Target: $5 → $1.75
Current: $1.94
Upside: -9.79%
Turnstone Biologics
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.46
Upside: +713.80%
ImmunityBio
Aug 19, 2024
Maintains: Neutral
Price Target: $6 → $4.75
Current: $3.53
Upside: +34.75%
LENZ Therapeutics
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $24.89
Upside: +44.64%
Iovance Biotherapeutics
Jul 29, 2024
Downgrades: Neutral
Price Target: $19 → $10
Current: $10.13
Upside: -1.26%
Day One Biopharmaceuticals
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $13.87
Upside: +188.39%
Ocular Therapeutix
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $9.58
Upside: +56.58%
Jun 7, 2024
Maintains: Overweight
Price Target: $45 → $10
Current: $10.19
Upside: -1.82%
Jun 7, 2024
Downgrades: Neutral
Price Target: $48 → $51
Current: $54.28
Upside: -6.04%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $21.71
Upside: +61.22%
May 28, 2024
Upgrades: Overweight
Price Target: $2.25 → $3.5
Current: $1.19
Upside: +195.36%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.87
Upside: +140.64%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $6.92
Upside: +333.53%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $3.15
Upside: +534.92%
Apr 5, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.00
Upside: +100.00%
Mar 27, 2024
Maintains: Overweight
Price Target: $105
Current: $59.52
Upside: +76.43%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $1.47
Upside: +582.59%
Mar 11, 2024
Initiates: Overweight
Price Target: $43
Current: $47.09
Upside: -8.69%
Mar 1, 2024
Maintains: Overweight
Price Target: $5 → $7
Current: $2.75
Upside: +154.55%
Feb 29, 2024
Maintains: Overweight
Price Target: $60 → $50
Current: $17.14
Upside: +191.72%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $6.86
Upside: +162.39%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $3.54
Upside: +606.21%
May 10, 2023
Assumes: Overweight
Price Target: $28
Current: $26.37
Upside: +6.18%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $19.79
Upside: +1.09%
May 12, 2022
Maintains: Overweight
Price Target: $50 → $20
Current: $6.00
Upside: +233.33%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.27
Upside: +18.11%
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.51
Upside: +1,872.39%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $6.71
Upside: +421.61%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $2.76
Upside: +2,073.91%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $7.08
Upside: +154.42%